Trial Profile
A Randomized Trial Comparing Treatment With Aflibercept and Ranibizuamab for Macular Edema After Branch Retinal Vein Occlusion
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Retinal oedema
- Focus Therapeutic Use
- 02 Dec 2020 Planned End Date changed from 1 Apr 2021 to 1 Aug 2022.
- 02 Dec 2020 Planned primary completion date changed from 1 Mar 2020 to 1 Nov 2021.
- 02 Dec 2020 Status changed from not yet recruiting to recruiting.